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Health-Related Quality of Life in I-125 Prostate
Brachytherapy Patients Treated with and without 
Volume-Reducing Hormone Therapy: Results 
of a Short-Term Prospective Study
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Saskia Houterman, Ph.D.,2,4 Ad Vingerhoets, Ph.D.,5 and Ad Hendrikx M.D.3
Abstract
Purpose: This study describes the differences in short-term effects of health-related quality of life (HRQOL) in
I-125 prostate brachytherapy patients who were treated with and without volume-reducing hormone therapy.
Patients and Methods: Prostate cancer patients (N  312) filled out questionnaires on HRQOL (European Or-
ganization of Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ]-C30 and EORTC-
QLQ-PR25) before treatment and 6 weeks and 3 months after treatment. HRQOL was compared between the
two groups: Patients who were receiving brachytherapy (n  233) and patients who were receiving brachyther-
apy with volume-reducing hormone therapy (n  79). Duration of androgen ablation was 9 months, starting 3
months before I-125 implantation.
Results: After treatment, patients reported significant and clinically relevant decreased scores on the following
subscales: Global health status, role functioning, social functioning, pain, insomnia, bowel symptoms and func-
tioning, and treatment-related functions, regardless of the therapy they received. Results showed that prostate
cancer patients receiving brachytherapy with volume-reducing hormone therapy also experienced lower treat-
ment-related functions and lower sexual function. Significant time by treatment interaction effects were found
for treatment-related functions. The subscale treatment-related functions was the only scale that showed a dif-
ference over time, between treatments, and time by treatment.
Conclusions: The differences in HRQOL between brachytherapy and brachytherapy with volume-reducing
hormone therapy are small; they both decrease HRQOL and increase treatment-related problems. A long-term
prospective study on long-term effects on HRQOL is needed to obtain a more comprehensive view of the con-
sequences of a specific treatment modality over time. Our results can help to identify the problems patients
face after brachytherapy with or without hormone therapy; these problems deserve additional attention dur-
ing the period of recovery.
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Introduction
PROSTATE CANCER is the most common malignancy in menin the western world.1 In 2005, 9,500 men in the Nether-
lands received a diagnosis of prostate cancer, and this num-
ber is expected to increase to 15,000 by the year 2015.2
Brachytherapy is one of the treatment options for localized
prostate cancer. Sometimes brachytherapy patients undergo
volume-reducing hormone therapy because of a large
prostate volume or high-risk tumor characteristics (eg, high
prostate-specific antigen [PSA] levels, high Gleason scores,
or a high tumor stage).
Prostate cancer can affect general health-related quality of
life (HRQOL) (e.g., physical, psychological, and social func-
1CoRPS—Center of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, The Netherlands.
2Comprehensive Cancer Centre South (CCCS), Eindhoven Cancer Registry, Eindhoven, The Netherlands.
3Department of Urology, Catharina Hospital, Eindhoven, The Netherlands.
4MMC Academy, Maxima Medical Centre, Veldhoven, The Netherlands.
5Clinical Psychology Section, Tilburg University, Tilburg, The Netherlands.
tioning) and disease-specific HRQOL (eg, urinary, sexual,
and bowel functioning).3–6 Differences in effects on HRQOL
between treatment methods exist. In this study, we com-
pared “brachytherapy” with “brachytherapy with volume-
reducing hormone therapy” on HRQOL aspects.
Urinary complaints after prostate brachytherapy are com-
mon but only rarely severe.7 Moreover, they appear to peak
1 month after brachytherapy and subsequently return to
their baseline values after 1 year.8 Compared with a control
group of patients with prostate cancer who were not treated,
brachytherapy patients did not differ in overall urinary
HRQOL at follow-up (mean  26 months).9 Another study,
however, found that during a 4-year period (2.6 years to 6.2
years after treatment), urinary incontinence worsened in pa-
tients treated with brachytherapy.6
Patients receiving hormone therapy only reported more
physical discomfort 1 year after diagnosis compared with
men who did not receive hormone therapy.10 Furthermore,
among men who were sexually potent before diagnosis, 80%
of patients treated with hormone therapy reported being im-
potent after one year.10 In addition, patients who had re-
ceived hormone therapy reported reduced energy, and
poorer sexual and urinary function; they were more both-
ered by their urinary and sexual function than patients un-
dergoing radical prostatectomy or radiotherapy.5 Patients
treated with hormone therapy for at least 12 months had os-
teoporosis, unfavorable body composition, sexual dysfunc-
tion, and reduced overall HRQOL scores.11
To summarize, both brachytherapy and hormone therapy
appear to have a negative influence on HRQOL. To the best
of our knowledge, however, only one study has been pub-
lished that compared HRQOL between prostate cancer pa-
tients treated with brachytherapy versus brachytherapy with
volume-reducing hormone therapy.12 Compared with pa-
tients treated with brachytherapy, brachytherapy with vol-
ume-reducing hormone therapy led to lower HRQOL in all
domains 29 months after treatment. This was significant and
clinically relevant for urinary bother, sexual function/
bother, and hormone function/bother. Despite its relevance,
that study was cross-sectional and could therefore not reg-
ister changes between treatments over time. Therefore, we
examined the short-term influence of brachytherapy and
brachytherapy with volume-reducing hormone therapy on




This study was conducted at the Catharina Hospital, Eind-
hoven, the Netherlands. A total of 386 patients who had re-
ceived a diagnosis of T1-T2 prostate cancer in the period be-
tween July 2000 and November 2004 were asked to
participate in this study.
All patients were treated with I-125 prostate brachyther-
apy. Brachytherapy was often applied with volume-reduc-
ing hormone therapy to reduce the volume of the prostate
in patients with prostate gland volume 60 cc or to exter-
minate the influence of testosterone on the tumor in high-
risk patients.13 A majority was treated with a combination
of antiandrogen and LHRH (luteinizing hormone-releasing
hormone) analogues (70%), some were treated with only an-
tiandrogens (19%), and some were treated with only LHRH
analogues (11%) (Table 1). Duration of androgen ablation
was 9 months, starting 3 months before I-125 implantation.
Data collection
Patients were asked to complete our measure at three
points in time: Before treatment (T1), 6 weeks after the start
of treatment (T2), and 3 months after treatment (T3). Thus,
in the case of patients treated with brachytherapy only, they
received the first questionnaire before brachytherapy. In the
case of patients treated with brachytherapy with volume-re-
ducing hormone therapy, they received the first question-
naire before the start of hormone therapy and thus 3 months
before brachytherapy. Measurements two and three were
similar in both groups—namely 6 weeks and 3 months after
brachytherapy.
Patients were reassured that nonparticipation did not have
any consequences for their follow-up care or treatment. Re-
turned questionnaires only contained a study number that
guaranteed anonymity. The Medical Ethics Committee of
Catharina Hospital approved this study. Written informed
consent was obtained from every patient after the study pro-
cedure had been fully explained.
Measures
Patient data, including age, tumor-node-metastasis-classi-
fication,14 pretreatment PSA, Gleason score, grade, and pri-
mary treatment were derived from patients’ medical records.
The European Organization of Research and Treatment of
Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-
C30) version 3.0 was used to measure global HRQOL.15 This
questionnaire contains five functional scales (physical, role,
emotional, cognitive, and social functioning), a global
HRQOL scale, three symptom scales (nausea and vomiting,
fatigue, and pain), and six single items (dyspnea, insomnia,
appetite loss, constipation, diarrhea, and financial difficul-
ties).
Urologic, bowel, and sexual functioning were measured
with the EORTC-QLQ PR25.16 This questionnaire contains
five scales (urinary problems, bowel symptoms and func-
tioning, treatment-related functions, sexual functioning, and
sexual activity).
The response format of the EORTC-QLQ-C30 and the
EORTC-QLQ-PR25 was a Likert scale. According to standard
scoring procedures, all scales were linearly converted to a 0
to 100 scale, with higher scores indicating better functioning.
Statistical analyses
The Statistical Package for the Social Sciences (SPSS 12.0.0
for Windows) was used for all data analyses. Patient char-
acteristics and clinical parameters were described in per-
centages and were analyzed using chi-square tests for cate-
gorical variables.
Linear regression analyses were carried out to investigate
the association between patient characteristics (age, stage,
grade, pretreatment PSA and Gleason score) with the sub-
scale scores of the EORTC-QLQ-C30 and EORTC-QLQ-PR25.
On the basis of the univariate results, multivariate models
were constructed to determine which of the patient and tu-
mor characteristics were associated independently with
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HRQOL outcomes. We controlled for these variables in the
analysis of variance (general linear repeated-measures
model), which was used to compare HRQOL scores between
patients treated with brachytherapy or brachytherapy with
volume-reducing hormone therapy, at three points in time.
P values are presented for within-subjects effects over time
(before treatment and 6 weeks and 3 months after treatment),
between-subjects effects for treatment (brachytherapy or
brachytherapy with volume-reducing hormone therapy),
and time by treatment interaction effects. These P values are
all Greenhouse-Geisser corrected except for the subscale con-
stipation, where sphericity was assumed. P values less than
0.01 were considered statistically significant and are in-
cluded in the text. P values less then 0.05 are only mentioned
in the tables. We used Norman’s “rule of thumb” that the
threshold of discrimination for clinically relevant changes in
HRQOL for a chronic disease appears to be approximately
half a standard deviation.17
Results
Sociodemographic characteristics
Three hundred and twelve (81%) of the 386 suitable prostate
brachytherapy patients returned a completed questionnaire at
least once (Table 1). Before treatment, 295 patients (17 miss-
ing) returned the set of questionnaires; 6 weeks after treat-
ment, 266 patients (46 missing) returned questionnaires; and
3 months after treatment, 263 patients (49 missing) returned
questionnaires. All of them underwent I-125 brachytherapy,
and 79 of them also underwent volume-reducing hormone
therapy. No statistically significant differences in age at the
time of the survey, Gleason score, pretreatment PSA, stage,
and grade were found between both treatment groups.
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n  233 n  79
n (%) n (%) P value
Age at time of survey (years)
41–50 5 (2) 1 (1) 0.50
51–60 51 (22) 12 (15)
61–70 119 (51) 47 (60)
70 58 (25) 19 (24)
Gleason
2–4 26 (11) 10 (13) 0.80
5–7 203 (87) 69 (87)
8 1 (0) 0 (0)
Unknown 3 (1) 0 (0)
PSA ng/mL (pretreatment)
1–5 59 (25) 15 (19) 0.62
6–10 117 (50) 43 (54)
11–15 36 (16) 12 (15)
16–20 12 (5) 5 (6)
21–25 3 (1) 3 (4)
25 5 (2) 1 (1)
Missing values 1 (0) 0 (0)
Stage
T1c 133 (57) 50 (63) 0.67
T2a 65 (28) 21 (27)
T2b 11 (5) 2 (3)
T2c 24 (10) 6 (8)
Gradea
1 28 (12) 10 (13) 0.79
2 189 (81) 67 (85)
3 2 (1) 0 (0)
Missing values 14 (6) 2 (3)
Primary treatment
Brachytherapy 233 (100) 0 (0)
Brachytherapy  antiandrogens  0 (0) 55 (70)
LHRH-analogues
Brachytherapy  antiandrogens 0 (0) 15 (19)
Brachytherapy  LHRH-analogues 0 (0) 9 (11)
aGrade was based on the tumor-node-metastasis clinical classification.14 Grade 1 is comparable to a Gleason score of 2 to 4, grade 2 is com-
parable to a Gleason score of 5 to 7, and grade 3 is comparable to a Gleason score of 8 to 10.
PSA  prostate-specific antigen; LHRH  luteinizing hormone-releasing hormone.
Differences in HRQOL over time
EORTC-QLQ-C30 subscale scores in both patient groups
changed significantly between the three measurements.
Globally, scores decreased after treatment, increased again
between 6 weeks and 3 months after treatment, but never
reached the pretreatment level again. Statistically significant
and clinically relevant differences17 between measurements
1, 2, and 3 were found for global health status (P  0.001),
role functioning (P  0.001), social functioning (P  0.001),
fatigue (P  0.001), pain (P  0.001), and insomnia (P 
0.001). For example, values for the subscale global health sta-
tus decreased significantly 6 weeks after treatment, but after
3 months, the self-reported global health status improved
again for both treatment groups. 
Scores on the EORTC-QLQ-PR25 showed a similar pat-
tern; they decreased after treatment, followed by an increase
between 6 weeks and 3 months after treatment, but they also
failed to reach pretreatment levels. Repeated measures
showed significant and clinically relevant decreases over
time for the subscales bowel symptoms and functioning (P 
0.001), and treatment-related functions (P  0.001). These
findings demonstrate an increase of these prostate cancer-re-
lated complaints, regardless of the treatment. Incontinence
aids were used by too few respondents, so they were dis-
carded from analysis.
Differences in HRQOL between treatment methods
Statistically significant effects for treatment (brachyther-
apy versus brachytherapy with volume-reducing hormone
therapy) were not found for the subscales of the EORTC-
QLQ-C30. 
For the EORTC-QLQ-PR25, statistically significant and
clinically relevant differences between the two treatment
methods were found for the subscales treatment-related
functions (P  0.001) and sexual functioning (P  0.001). The
average scores for the significant subscales were lower for
patients who received brachytherapy with volume-reducing
hormone therapy compared with patients who were treated
with brachytherapy only.
Differences in HRQOL over time for treatment methods
Significant time by treatment interaction effects for the
subscales of both questionnaires was only found for treat-
ment-related functions (P  0.001). It appeared that a greater
reduction in HRQOL was found over time on this subscale
when receiving brachytherapy with volume-reducing hor-
mone therapy in contrast to treatment with brachytherapy
only.
Discussion
This study examined the short-term influence of
brachytherapy and brachytherapy with volume-reducing
hormone therapy on HRQOL in patients with T1-T2 prostate
cancer in a prospective study. Both brachytherapy and
brachytherapy with volume-reducing hormone therapy neg-
atively influenced HRQOL (global health status, role func-
tioning, social functioning, pain, insomnia) and caused treat-
ment-related problems (bowel symptoms and functioning,
treatment-related functions, and sexual functioning) 6 weeks
and 3 months after treatment. The differences in HRQOL be-
tween brachytherapy and brachytherapy with volume-re-
ducing hormone therapy were small.
To date, no prospective studies have been published that
have as a primary objective to compare HRQOL over time
between patients treated with either brachytherapy or
brachytherapy with volume-reducing hormone therapy.
Therefore, our results are difficult to compare with previ-
ous findings. A recent prospective study among T1 and T2
prostate cancer patients, however, concluded that those
treated with brachytherapy reported having long-lasting
urinary irritation, bowel and sexual symptoms, and tran-
sient problems with vitality or hormone function. Fur-
thermore, adjuvant hormone therapy was associated with
worse outcomes across multiple quality-of-life domains
among patients who were receiving brachytherapy.18 De-
spite the fact that comparing brachytherapy patients
treated with and without volume-reducing hormone ther-
apy was not the objective of that study and despite the fact
that different questionnaires were used, it partly confirms
our results.
A Dutch study among 127 patients with low-stage prostate
cancer who were treated with brachytherapy that did use the
same questionnaires also found a decrease in HRQOL 4
weeks after treatment.19 One year after implant, HRQOL of
the patients was at least equal to preimplant scores, which
suggests that many of the negative effects may recover in the
long term. This confirms the reports that demonstrate that
acute side effects after brachytherapy for prostate cancer ap-
pear to peak 1 month after brachytherapy and subsequently
return to their baseline values at 1 year.8 In addition, after
brachytherapy, dysuria is a relatively common complaint,
but at approximately 45 months after therapy, it appears to
have been resolved in almost all patients.7
According to a Japanese study, morbidity (associated with
brachytherapy followed by external beam radiotherapy) was
highest during the first month of treatment, and it affected
HRQOL significantly. Most outcome measures, however,
showed a recovery to baseline levels 12 months after radia-
tion therapy.20 Finally, a Swedish study on HRQOL after ex-
ternal beam radiotherapy and brachytherapy revealed that
the negative contribution from neoadjuvant androgen de-
privation therapy on symptom development seemed to be
substantial but mostly transitory.21
Our study also showed a decrease in HRQOL after treat-
ment followed by an increase between 6 weeks and 3 months
after treatment. Unlike the studies described above, how-
ever, our HRQOL scores failed to reach the pretreatment
level again within 3 months. This period is probably too short
to show a complete recovery. An additional follow-up mea-
surement to this study (1 year after treatment) could pos-
sibly demonstrate a complete recovery in HRQOL.
Patient-reported analyses of the effects of volume-reduc-
ing hormone therapy on HRQOL after brachytherapy are
scarce. Only one German study compared HRQOL in
prostate cancer patients (n  134) who were treated with
only brachytherapy with patients who received brachyther-
apy with volume-reducing hormone therapy.12 That study
reported lower HRQOL on all domains of the Expanded
Prostate Cancer Index questionnaire in patients who were
treated with brachytherapy with volume-reducing hormone
therapy compared with patients who were treated with










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































however, were its cross-sectional nature and the fact that it
compared HRQOL 2 to 50 months after treatment.
In our study, we did not find a HRQOL difference in all
domains between the two treatments. It appeared that
prostate cancer patients who received brachytherapy with
volume-reducing hormone therapy experienced more nega-
tive effects of their treatment (lower treatment-related func-
tions and worse sexual functioning) compared with patients
who were treated with brachytherapy only. Comparison of
the findings of both studies is not possible, given the differ-
ent questionnaire and the substantial difference in the tim-
ing of the measures.
Other studies22–24 that compared both treatment groups
did not include HRQOL measures. Potency rates decreased
significantly after brachytherapy with volume-reducing hor-
mone therapy compared with brachytherapy alone 5 years
after treatment (76% versus 52%).22 Furthermore, rectal func-
tion after brachytherapy with volume-reducing hormone
therapy was slightly worse than after brachytherapy only.
This difference, however, did not reach statistical signifi-
cance.23 Finally, volume-reducing hormone therapy was
found to be associated with an significantly increased risk of
urinary retention.24
Sexual functioning was both statistically worse in patients
in the volume-reducing hormone therapy group before treat-
ment compared with the brachytherapy only group. The dif-
ference in sexual functioning, however, between patients
treated with or without volume-reducing hormone therapy
was probably not related to therapy, because a statistically
significant difference was already present before the onset
of therapy. The fact that sexual functioning was not signifi-
cant in the “time by treatment analysis” confirms this idea.
The subscale treatment-related functions was the only scale
that showed a difference over time, between treatments, and
time by treatment. 
The present study has some limitations. First, maybe not
all hormone treatments are comparable. In this study, the
majority of patients were treated with antiandrogen or
LHRH analogues, or a combination of both (89%). There
were patients (11%) who received other hormone therapies,
such as cyproterone acetate or leuprorelin acetate. These
therapies may have a different effect on HRQOL. This could
not be evaluated in this study because of the low number of
patients receiving these treatments.
In addition, comorbidity is a factor that can influence
HRQOL and is therefore often controlled for in HRQOL
studies.25–27 Comorbidity might also interfere with our re-
sults and is not corrected for in this research, because infor-
mation on comorbidity was not available. We have no rea-
son to suspect, however, that comorbidity is present more in
either treatment group.
Finally and most importantly, the current study only fo-
cused on relatively short-term effects (up to 3 months). It is
possible that, after treatment, patients who were treated with
hormone therapy report a lower HRQOL because they are
still bothered by the effects of hormone therapy, which wear
off more slowly compared with the treatment effects of
brachytherapy. A long-term prospective study on long-term
effects on HRQOL is needed to obtain a more comprehen-
sive view of the consequences of a specific treatment mo-
dality over time.
Conclusion
We think that the results of this study add importantly to
the limited information available on HRQOL in patients with
prostate cancer who receive brachytherapy or brachytherapy
with volume-reducing hormone therapy, especially because
of its prospective nature. Insight into the effects of
brachytherapy on HRQOL is important as this therapy be-
comes more standard in the treatment of men with early-
stage prostate cancer.
The differences in HRQOL in patients who are treated
with brachytherapy or brachytherapy with volume-reducing
hormone therapy are small. Both treatments cause a decrease
in HRQOL and increase in treatment-related problems. Our
results can help to identify the problems patients face after
brachytherapy with or without hormone therapy; these
problems deserve additional attention during the period of
recovery. Long-term prospective studies on the long-term ef-
fects on HRQOL are needed, however, to obtain a more com-
prehensive view of the consequences of a specific treatment
modality over time.
Disclosure Statement
No competing financial interests exist.
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